GeneFerm Biotechnology Co. Ltd.(TW:1796)
NT$28.00+0.45 (+1.63%)
TW:1796
GeneFerm Biotechnology Co. Ltd. financials statements
NT$28.00
At close:+0.45 (+1.63%)
GeneFerm Biotechnology Co. Ltd. (1796) Ratios
GeneFerm Biotechnology Co. Ltd. Ratios
TW:1796's free cash flow for Q2 2026 was NT$12.37M. For the 2026 fiscal year, TW:1796's free cash flow was decreased by NT$-13.39M and operating cash flow was NT$25.77M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.75 | 3.07 | 2.09 | 1.56 | 1.77 |
| Quick Ratio | 2.55 | 1.83 | 1.27 | 0.97 | 1.51 |
| Cash Ratio | 1.77 | 0.91 | 0.63 | 0.42 | 1.25 |
| Solvency Ratio | 0.22 | 0.16 | 0.70 | 0.40 | 0.18 |
| Operating Cash Flow Ratio | 0.63 | 0.06 | 1.00 | 0.51 | 0.26 |
| Short-Term Operating Cash Flow Coverage | 3.00 | 0.23 | 4.21 | 1.12 | 0.33 |
| Net Current Asset Value | NT$ 131.48M | NT$ 53.66M | NT$ 114.59M | NT$ 14.68M | NT$ 195.96M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.25 | 0.21 | 0.11 | 0.18 | 0.35 |
| Debt-to-Equity Ratio | 0.40 | 0.31 | 0.14 | 0.26 | 0.62 |
| Debt-to-Capital Ratio | 0.28 | 0.24 | 0.12 | 0.21 | 0.38 |
| Long-Term Debt-to-Capital Ratio | 0.20 | 0.14 | 0.00 | 0.01 | 0.04 |
| Financial Leverage Ratio | 1.57 | 1.45 | 1.32 | 1.43 | 1.76 |
| Debt Service Coverage Ratio | 2.78 | 1.53 | 4.09 | 1.30 | 0.32 |
| Interest Coverage Ratio | 7.40 | -7.99 | 36.80 | 29.65 | 10.82 |
| Debt to Market Cap | 0.12 | 0.08 | 0.01 | 0.04 | 0.21 |
| Interest Debt Per Share | 7.97 | 6.05 | 3.18 | 5.39 | 11.90 |
| Net Debt to EBITDA | 0.38 | 2.20 | 0.03 | 0.73 | -0.60 |
| Profitability Margins | |||||
| Gross Profit Margin | 28.18% | 18.56% | 36.07% | 35.04% | 36.88% |
| EBIT Margin | 6.04% | -4.42% | 19.86% | 17.99% | 14.88% |
| EBITDA Margin | 17.04% | 10.81% | 29.11% | 25.77% | 23.84% |
| Operating Profit Margin | 6.80% | -6.81% | 19.35% | 17.87% | 15.15% |
| Pretax Profit Margin | 5.12% | -5.27% | 19.33% | 17.38% | 13.48% |
| Net Profit Margin | 4.26% | -4.32% | 15.70% | 14.74% | 10.99% |
| Continuous Operations Profit Margin | 4.26% | -4.32% | 15.70% | 14.74% | 10.99% |
| Net Income Per EBT | 83.19% | 82.02% | 81.22% | 84.79% | 81.56% |
| EBT Per EBIT | 75.36% | 77.38% | 99.91% | 97.26% | 88.94% |
| Return on Assets (ROA) | 2.25% | -1.96% | 10.60% | 7.86% | 4.36% |
| Return on Equity (ROE) | 3.53% | -2.86% | 13.96% | 11.25% | 7.68% |
| Return on Capital Employed (ROCE) | 4.10% | -3.51% | 15.58% | 11.92% | 8.94% |
| Return on Invested Capital (ROIC) | 3.30% | -2.76% | 12.03% | 9.02% | 5.26% |
| Return on Tangible Assets | 2.26% | -1.97% | 10.62% | 7.86% | 4.36% |
| Earnings Yield | 1.44% | -1.16% | 4.05% | 3.38% | 3.26% |
| Efficiency Ratios | |||||
| Receivables Turnover | 6.90 | 5.12 | 6.75 | 5.24 | 4.98 |
| Payables Turnover | 30.12 | 33.95 | 59.25 | 34.92 | 28.42 |
| Inventory Turnover | 2.56 | 2.56 | 3.26 | 2.89 | 2.87 |
| Fixed Asset Turnover | 1.01 | 0.73 | 1.04 | 0.79 | 0.97 |
| Asset Turnover | 0.53 | 0.45 | 0.68 | 0.53 | 0.40 |
| Working Capital Turnover Ratio | 1.90 | 2.15 | 4.65 | 2.71 | 1.39 |
| Cash Conversion Cycle | 183.59 | 203.23 | 159.72 | 185.60 | 187.60 |
| Days of Sales Outstanding | 52.93 | 71.34 | 54.08 | 69.65 | 73.30 |
| Days of Inventory Outstanding | 142.78 | 142.64 | 111.81 | 126.40 | 127.13 |
| Days of Payables Outstanding | 12.12 | 10.75 | 6.16 | 10.45 | 12.84 |
| Operating Cycle | 195.71 | 213.98 | 165.89 | 196.05 | 200.44 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 2.40 | 0.20 | 4.60 | 2.96 | 2.83 |
| Free Cash Flow Per Share | 1.83 | -0.35 | 2.87 | -3.77 | -0.84 |
| Dividend Paid and CapEx Coverage Ratio | 4.24 | 0.08 | 1.42 | 0.38 | 0.75 |
| Capital Expenditure Coverage Ratio | 4.24 | 0.36 | 2.67 | 0.44 | 0.77 |
| Operating Cash Flow Coverage Ratio | 0.31 | 0.03 | 1.49 | 0.56 | 0.24 |
| Operating Cash Flow to Sales Ratio | 0.15 | 0.02 | 0.24 | 0.19 | 0.21 |
| Free Cash Flow Yield | 3.79% | -0.75% | 3.86% | -5.64% | -1.90% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 68.93 | -87.04 | 24.72 | 29.60 | 30.59 |
| Price-to-Sales (P/S) Ratio | 2.95 | 3.74 | 3.88 | 4.36 | 3.37 |
| Price-to-Book (P/B) Ratio | 2.45 | 2.47 | 3.45 | 3.33 | 2.35 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 26.36 | -133.39 | 25.90 | -17.73 | -52.73 |
| Price-to-Operating Cash Flow Ratio | 20.14 | 240.87 | 16.19 | 22.59 | 15.68 |
| Price-to-Earnings Growth (PEG) Ratio | -0.30 | 0.74 | 0.74 | 0.53 | 0.04 |
| Enterprise Value Multiple | 17.72 | 36.78 | 13.36 | 17.66 | 13.53 |
| Enterprise Value | 2.04B | 2.07B | 3.09B | 2.88B | 1.68B |
| EV to EBITDA | 17.72 | 36.78 | 13.36 | 17.66 | 13.53 |
| EV to Sales | 3.02 | 3.98 | 3.89 | 4.55 | 3.23 |
| EV to Free Cash Flow | 26.94 | -141.86 | 25.97 | -18.49 | -50.48 |
| EV to Operating Cash Flow | 20.59 | 256.16 | 16.22 | 23.56 | 15.01 |
| Tangible Book Value Per Share | 19.67 | 18.97 | 21.52 | 20.07 | 18.81 |
| Shareholders’ Equity Per Share | 19.70 | 19.01 | 21.56 | 20.09 | 18.84 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.17 | 0.18 | 0.19 | 0.15 | 0.18 |
| Revenue Per Share | 16.33 | 12.57 | 19.17 | 15.33 | 13.16 |
| Net Income Per Share | 0.70 | -0.54 | 3.01 | 2.26 | 1.45 |
| Tax Burden | 0.83 | 0.82 | 0.81 | 0.85 | 0.82 |
| Interest Burden | 0.85 | 1.19 | 0.97 | 0.97 | 0.91 |
| Research & Development to Revenue | 0.05 | 0.06 | 0.04 | 0.04 | 0.05 |
| SG&A to Revenue | 0.16 | 0.20 | 0.13 | 0.15 | 0.17 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 2.86 | -0.29 | 1.53 | 1.11 | 1.59 |
Currency in TWD
